Smoking Cessation - 06/02/14
, David M. Daughton, MSRésumé |
Cigarette smoking is a major preventable cause of morbidity and mortality. It is the major risk factor for chronic obstructive pulmonary disease in the developed world. Smoking is a chronic relapsing disease. Optimal treatment includes nonpharmacologic support, together with pharmacotherapy. All clinicians should be comfortable with the use of nicotine replacement therapy, bupropion, and varenicline. Second-line therapies can be used by those familiar with their use. Effective use of these medications requires their integration into an effective management plan, which is likely to be a long-term undertaking, involving several cycles of remission and relapse.
Le texte complet de cet article est disponible en PDF.Keywords : Smoking, Cessation, Treatment, Pharmacotherapy
Plan
| Disclosures: Since 2010, S.I. Rennard has consulted with Pfizer on the topic of smoking cessation and conducted clinical trials sponsored by Pfizer. He has also consulted on other topics for GlaxoSmithKline which has smoking cessation products. |
Vol 35 - N° 1
P. 165-176 - mars 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
